Biogen announced Tuesday that its R&D chief is leaving for a venture capital firm and CEO job, only six months after the high-profile failure of the company’s Alzheimer’s drug. His duties will be taken over by Al Sandrock, Biogen’s chief medical officer, who has become more synonymous with Biogen (BIIB) than any other executive. In the end, that could be a good thing.

Investors who already doubt Biogen’s ability to build for the future will only get more skittish, of course. Analysts at J.P. Morgan wrote that the announcement “does little to instill confidence in the company’s R&D outlook/direction.” And Sandrock’s presence won’t do anything to ease indigestion caused by the general feeling that Biogen bet too much on the failed Alzheimer’s medicine, aducanumab, and did not hedge enough against that failure — even though every Alzheimer’s drug tested in the past decade has proved ineffective.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy